Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T07:29:59.788Z Has data issue: false hasContentIssue false
  • English
  • Français

Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated with Major Depressive Disorder: Pooled Data from 9 Short-Term, Double-blind, Placebo-Controlled Trials

Published online by Cambridge University Press:  07 November 2014

Karen A. Tourian ,
Qin Jiang  and
Philip T. Ninan
Karen A. Tourian*
Affiliation:
CR&D Neuroscience, Wyeth, a company of the Pfizer Group
Qin Jiang
Affiliation:
Pfizer Inc, formerly Wyeth Research
Philip T. Ninan
Affiliation:
Pfizer Inc, formerly Wyeth Research
*
Karen A. Tourian, MD, Wyeth, a company of the Pfizer Group, Division Wyeth Research, Coeur Défense, Tour A, La Défense 4, 110 Esplanade du Générate de Gaulle 92931 Paris, La Défense Cedex, France. Tel: 33-01-41-02-78-10; Fax:, 33-01-41-02-74-79. E-mail:, [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: This analysis evaluated the effects of the serotonin-norepinephrine reuptake inhibitor, desvenlafaxine (administered as desvenlafaxine succinate), on anxiety symptoms associated with depression.

Methods: Data were pooled from 9 randomized, placebo-controlled, double-blind, 8 week studies of desvenlafaxine (50-400 mg/day, fixed or flexible dose) in patients with major depressive disorder (MDD), without a primary anxiety diagnosis. Changes from baseline in scores on the anxiety/somatization factor of the 17-item Hamilton Rating Scale for Depression (HAM-D17) and on the Covi Anxiety Scale at the final evaluation (last observation carried forward) were compared between desvenlafaxine and placebo groups using analysis of covariance.

Results: In the overall data set (intent to treat n=2,913 [desvenlafaxine, n=1,805; placebo, n=1,108]), desvenlafaxine was associated with significantly greater reductions compared with placebo in scores on the HAM-D17 anxiety/somatization factor (-3.41 vs -2.92, P<.001) and Covi Anxiety Scale (-1.35 vs -1.04, P<.001). In the subset of fixed-dose studies, significant differences were observed for all dose groups on the HAM-D17 anxiety/somatization factor (P≤.OH), and for the 50, 100, and 200 mg/day dose groups on the Covi Anxiety Scale (all P≤.015 vs placebo).

Conclusions: Desvenlafaxine was associated with significantly greater improvement in anxiety symptoms compared with placebo in patients with MDD.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 3 , March 2010 , pp. 187 - 193
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Fawcett, J, Clark, DC, Scheftner, WA, Gibbons, RD. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983;40:73–84.Google Scholar
2.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*TD. Psychol Med. 2004;34:1299–1308.Google Scholar
3.Fava, M, Rush, AJ, Alpert, JE, et al.Difference in treatment outcome In outpatients with anxious versus nonanxlous depression: A STAR*D report. Am J Psychiatry. 2008;165:342–351.Google Scholar
4.Davidson, JR, Meoni, P, Haudiquet, V, Cantillon, M, Hackett, D. Achieving remission with ven-lafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4–13.Google Scholar
5.Joffe, RT, Bagby, RM, Levitt, A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150:1257–1258.Google Scholar
6.Tollefson, GD, Holman, SL, Sayler, ME, Potvin, JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:50–59.Google Scholar
7.Nelson, JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety. 2010;27:12–18.Google Scholar
8.Keller, MB, Krystal, JH, Hen, R, Neumelster, A, Simon, NM. Untangling depression and anxiety: clinical challenges. J Clin Psychiatry. 2005;66:1477–1484.Google Scholar
9.Soomro, GM, Altman, D, Rajagopal, S, Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.Google Scholar
10.Dell'Osso, B, Nestadt, G, Allen, A, Hollander, E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry. 2006;67:600–610.Google Scholar
11.Pollack, M, Mangano, R, Entsuah, R, Tzanls, E, Simon, NM, Zhang, Y. A randomized controlled trial of venlafaxlne ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology(Berl). 2007;194:233–242.Google Scholar
12.Katon, WJ. Clinical practice. Panic disorder. N Engl J Med. 2006;354:2360–2367.Google Scholar
13.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):20–26.Google Scholar
14.Frlcchione, G. Clinical practice. Generalized anxiety disorder. N Engl J Med. 2004;351:675–682.Google Scholar
15.Ballenger, JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):11–19.Google Scholar
16.Feighner, JP. Entsuah, AR, McPherson, MK. Efficacy of once-daily venlafaxlne extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord. 1998;47:55–62.Google Scholar
17.Nutt, DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60(suppl 17):23–27.Google Scholar
18.Papakostas, GI, Trivedl, MH, Alpert, JE, et al.Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms In major depressive disorder: a meta-analysis of Individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008;42:134–140.Google Scholar
19.Deecher, DC, Beyer, CE, Johnston, Get al.Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657–665.Google Scholar
20.Desvenlafaxine [package insert]. Collegeville, PA: Wyeth Pharmaceuticals; 2008.Google Scholar
21.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, J-M, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate In the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338–347.Google Scholar
22.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677–688.Google Scholar
23.Liebowitz, M, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663–1672.Google Scholar
24.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerabillty of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877–1890.Google Scholar
25.Boyer, P, Montgomery, S, Lepola, U, et al.Efficacy, safety, and tolerabillty of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder In a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243–253.Google Scholar
26.Rudolph, RL, Entsuah, R, Chitra, R. A meta-analysis of the effects of venlafaxlne on anxiety associated with depression. J Clin Psychopharmacol. 1998;18:136–144.Google Scholar
27.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:53–61.Google Scholar
28.Rynn, M, Russell, J, Erickson, J, et al.Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25:182–189.Google Scholar
29.Lleberman, DZ, Montgomery, SA, Tourian, KAet al.A pooled analysis of two placebo-controlled trials of desvenlafaxine In major depressive disorder. Int Clin Psychopharmacol. 2008;23:188–197.Google Scholar
30.Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
31.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.Google Scholar
32.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.Google Scholar
33.Guy, W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockvllle, MD: US Department of Health, Education, and Welfare; 1976.Google Scholar
34.Lipman, RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982; 18:69–77.Google Scholar
35.Raskin, A, Schulterbrandt, J, Reatlg, N, McKeon, JJ. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:87–98.Google Scholar
36.Thase, ME, Kornstein, SG, Germain, J-M, Jiang, Q, Guico-Pabia, C, Ninan, PT. An Integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009; 14:144–154.Google Scholar
37.Thase, ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull. 2002;36(suppl 1):1–17.Google Scholar